Ionis Pharmaceuticals Files 8-K on Agreements and Equity Sales
Ticker: IONS · Form: 8-K · Filed: Nov 17, 2025 · CIK: 874015
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-securities
Related Tickers: IONS
TL;DR
IONIS filed an 8-K detailing new financial obligations and equity sales.
AI Summary
On November 11, 2025, Ionis Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and other events. This filing details financial obligations and equity transactions for Ionis Pharmaceuticals.
Why It Matters
This 8-K filing indicates new financial commitments and equity transactions for Ionis Pharmaceuticals, which could impact its financial structure and shareholder equity.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and financial obligations, which inherently carry financial risk.
Key Players & Entities
- IONIS PHARMACEUTICALS, INC. (company) — Registrant
- November 11, 2025 (date) — Date of earliest event reported
- 2855 Gazelle Court Carlsbad, CA 92010 (location) — Principal Executive Offices
FAQ
What type of material definitive agreement did Ionis Pharmaceuticals enter into?
The filing indicates the entry into a material definitive agreement that creates a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.
What other significant events are reported in this 8-K filing?
Besides the material definitive agreement, the filing also reports on unregistered sales of equity securities and other events.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 11, 2025.
What is the principal executive office address for Ionis Pharmaceuticals?
The principal executive offices are located at 2855 Gazelle Court, Carlsbad, CA 92010.
What is the Commission File Number for Ionis Pharmaceuticals?
The Commission File Number for Ionis Pharmaceuticals is 000-19125.
Filing Stats: 2,966 words · 12 min read · ~10 pages · Grade level 15.2 · Accepted 2025-11-17 16:06:20
Key Financial Figures
- $770.0 million — ed private offering (the "Offering") of $770.0 million aggregate principal amount of 0.00% Con
- $70.0 million — option to purchase up to an additional $70.0 million principal amount of Notes. The Notes we
- $0.001 — f the Company's common stock, par value $0.001 per share ("Common Stock"), for at leas
- $1,000 — price (as defined in the Indenture) per $1,000 principal amount of the Notes for each
- $98.10 — itial conversion price of approximately $98.10 per share of Common Stock). The initial
- $100.0 million — ed with a principal amount in excess of $100.0 million (or its foreign currency equivalent) in
- $751.2 m — from the Offering will be approximately $751.2 million, after deducting the initial purc
- $267.6 million — Company. The Company used approximately $267.6 million of the net proceeds from the Offering t
- $200.0 million — rom the Offering to repurchase for cash $200.0 million in aggregate principal amount of its 0%
Filing Documents
- d31230d8k.htm (8-K) — 47KB
- d31230dex41.htm (EX-4.1) — 598KB
- d31230dex991.htm (EX-99.1) — 11KB
- d31230dex992.htm (EX-99.2) — 15KB
- g31230dsp85a.jpg (GRAPHIC) — 5KB
- g31230g1115101145503.jpg (GRAPHIC) — 4KB
- g31230g1115101203722.jpg (GRAPHIC) — 4KB
- g31230g1116172418085.jpg (GRAPHIC) — 2KB
- g31230g1116172418398.jpg (GRAPHIC) — 2KB
- g31230g1116172418650.jpg (GRAPHIC) — 2KB
- g31230g1116172418900.jpg (GRAPHIC) — 2KB
- g31230g1116172419166.jpg (GRAPHIC) — 3KB
- 0001193125-25-284609.txt ( ) — 964KB
- ions-20251111.xsd (EX-101.SCH) — 2KB
- ions-20251111_lab.xml (EX-101.LAB) — 17KB
- ions-20251111_pre.xml (EX-101.PRE) — 11KB
- d31230d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All forward-looking statements included in this report, including statements regarding the Company's expected uses of the net proceeds from the Offering, are based upon information available to the Company as of the date of this report, which may change, and the Company assumes no obligation to update any such forward-looking statements. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. These statements are not guarantees of future performance and actual results could differ materially from the Company's current expectations. As a result, you are cautioned not to rely on these forward-looking statements. Factors that could cause or contribute to such differences include the risks and uncertainties discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on October 29, 2025, and other subsequent filings the Company makes with the Securities and Exchange Commission from time to time, as well as market risks, trends and conditions, and unanticipated uses of the net proceeds from the Offering. The Company assumes no obligation and does not intend to update the forward-looking statements provided, whether as a result of new information, future events or otherwise. Item9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Indenture, dated as of November 17, 2025, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee. 4.2 Form of Global Note, representing the Company's 0.00% Convertible Senior Notes due 2030 (included as Exhibit A to the I
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ionis Pharmaceuticals, Inc. Date: November 17, 2025 By: /s/ Patrick R. O'Neil P ATRICK R. O'N EIL Executive Vice President, Chief Legal Officer and General Counsel